Can I Take Vitamin B6 With Retatrutide? A Women's Health Guide

What You Need to Know Right Away

Retatrutide does not appear to interfere with how your body absorbs, metabolizes, or excretes vitamin B6. The short answer to "can I take vitamin B6 with retatrutide" is yes, at standard supplemental doses, with no special timing required. The longer answer depends entirely on which dose of B6 you are taking, because very high doses create their own neurological risk that has nothing to do with retatrutide but matters even more when your GI tract is already adapting to a powerful new medication.

Retatrutide is a triple GLP-1, GIP, and glucagon receptor agonist developed by Eli Lilly. In the Phase 2 dose-escalation trial published in the New England Journal of Medicine in 2023, participants receiving 12 mg weekly lost a mean of 24.2% of body weight at 48 weeks, an effect that exceeded the weight loss seen with approved dual and single agonists in comparable timeframes. Phase 3 trials are running as of early 2025, and no FDA approval has been issued yet.

Because retatrutide is still investigational, specific supplement interaction data from the manufacturer is sparse. What we can do is apply what is known about the drug's mechanism, the known pharmacology of vitamin B6, and the available evidence on high-dose B6 toxicity to give you a practical, honest answer.

Understanding Retatrutide's Mechanism and Why It Matters for Supplements

Triple agonism and GI effects

Retatrutide works by activating three separate hormone receptors simultaneously. GLP-1 receptor activation slows gastric emptying and reduces appetite. GIP receptor activation modulates insulin secretion and may augment fat oxidation. Glucagon receptor activation increases energy expenditure and promotes hepatic fat clearance. Together, these three pathways produced clinically meaningful reductions in liver fat and body weight in the Phase 2 cohort, including in participants with obesity and type 2 diabetes.

Slowed gastric emptying is the mechanism most relevant to supplements. Any oral supplement or medication taken alongside retatrutide may spend more time in the stomach before reaching the small intestine where absorption actually occurs. For most water-soluble vitamins including B6, this does not meaningfully reduce the total amount absorbed; it simply delays the peak.

What "pharmacokinetic" versus "pharmacodynamic" means for you

A pharmacokinetic interaction changes how much of a substance reaches your bloodstream. A pharmacodynamic interaction changes what that substance does once it is there. There is no established pharmacokinetic interaction between retatrutide and vitamin B6: retatrutide is not metabolized by the cytochrome P450 enzymes that handle many drug-supplement interactions, and GLP-1 receptor agonists as a class are eliminated via proteolytic degradation, not hepatic oxidation. B6 does not affect that degradation pathway.

The only theoretical pharmacodynamic concern comes from high-dose B6 neurotoxicity compounding any neuropathic risk a patient already carries. For most women starting retatrutide for obesity or metabolic disease, baseline peripheral neuropathy risk is low. For women with type 2 diabetes or long-term metformin use, that risk is already elevated, and layering high-dose B6 on top deserves more caution.

Vitamin B6 Basics: Why Women Take It and What the Evidence Says

Vitamin B6 (pyridoxine, pyridoxal, pyridoxamine, and their phosphorylated forms) is essential for more than 100 enzymatic reactions, most of them tied to amino acid and neurotransmitter metabolism. The active coenzyme form, pyridoxal-5-phosphate (PLP), is required for serotonin, dopamine, and GABA synthesis.

Women take B6 supplements for several specific reasons:

• Nausea of pregnancy and hyperemesis gravidarum. The FDA-approved combination of doxylamine and B6 (Diclegis/Bonjesta) uses 10 to 20 mg B6 per dose, well within a safe range.
• Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD). Several small trials suggest modest benefit at 50 to 100 mg/day, though a 2016 systematic review in BJOG found the evidence base remains weak.
• Oral contraceptive use. Combined oral contraceptives can reduce circulating B6 by up to 30%, which is one reason women on the pill sometimes report low mood and why low-dose B6 supplementation has been studied as a corrective.
• PCOS. Some women with PCOS follow dietary protocols that restrict processed foods and emphasize protein; because animal protein is a primary B6 source, some practitioners recommend monitoring B6 status in this group.

How much B6 is too much?

The National Institutes of Health Office of Dietary Supplements sets the Tolerable Upper Intake Level (UL) for vitamin B6 at 100 mg/day for adults. Chronic intake above that threshold, particularly doses in the 200 to 1,000 mg range sold as "mega-dose" neurological or hormone-balance supplements, is associated with sensory peripheral neuropathy. Symptoms include numbness and tingling in the hands and feet, difficulty walking, and in severe cases, loss of proprioception. A 2023 case series in the Annals of Internal Medicine documented neurological injury at doses as low as 150 mg/day taken for six or more months. Symptoms are often reversible after stopping high-dose B6, but recovery can take months.

The Retatrutide-B6 Interaction Dissected

Here is a simple framework for thinking about your personal risk level, organized by the dose of B6 you are taking:

Tier 1: Dietary B6 from food (1 to 3 mg/day) No interaction concern. Poultry, fish, potatoes, and non-citrus fruits supply most dietary B6. Retatrutide will not block your absorption of these amounts, and these amounts pose no neuropathy risk.

Tier 2: Standard multivitamin or prenatal vitamin B6 (2 to 25 mg/day) Still no clinically meaningful concern with retatrutide. The gastric-emptying delay may slightly shift peak B6 plasma levels by one to two hours, but total daily absorption is not expected to change. GLP-1 receptor agonist-mediated gastric emptying slowing has been studied most carefully with metformin and levothyroxine, where the clinical effect on drug exposure was small but measurable; for a water-soluble vitamin with a wide therapeutic window, this effect is unlikely to matter.

Tier 3: B6 for PMS or PMDD (50 to 100 mg/day) You are approaching the UL. The interaction with retatrutide remains pharmacodynamic rather than pharmacokinetic, but at 100 mg/day you have no safety buffer. Discuss with your prescribing clinician whether a lower dose achieves your PMS goals. A trial of 25 to 50 mg/day is worth considering; the published PMS literature does not show a clear dose-response relationship above 50 mg.

Tier 4: High-dose neurological or "hormone balance" B6 (100+ mg/day) This is where caution becomes genuine advice to stop or reduce. The neuropathy risk at these doses is independent of retatrutide, but because retatrutide itself is under Phase 3 evaluation with ongoing safety reporting, adding a known neurotoxic risk to the picture serves no one. The European Food Safety Authority reached a similar conclusion in its 2023 re-evaluation, tightening its guidance on high-dose B6 supplements.

Sex-Specific Physiology: How Being a Woman Changes the B6 Story

Women's B6 requirements and risks are not identical to men's, and the clinical literature has not always made this distinction clearly.

During reproductive years

The RDA for B6 is 1.3 mg/day for women aged 19 to 50. Estrogen and progesterone fluctuations across the menstrual cycle appear to affect B6 metabolism to a modest degree; luteal-phase increases in progesterone may transiently increase B6 turnover, which is one proposed mechanism behind the PMS-B6 hypothesis. The clinical evidence supporting B6 for PMS is suggestive but not definitive, and women should weigh modest potential benefit against the dose-dependent toxicity risk.

Perimenopause

Women in perimenopause using retatrutide for weight management or metabolic health are unlikely to have specific B6 interactions beyond those already described. Perimenopausal women often experience sleep disruption, mood changes, and new or worsening peripheral symptoms that could be mistaken for B6 toxicity if high doses are being taken concurrently. Baseline documentation of any tingling or numbness before starting both is good clinical practice.

Postmenopause

Postmenopausal women have a slightly higher RDA for B6 at 1.5 mg/day. No specific interaction data for retatrutide and B6 exists in this age group. Postmenopausal women on retatrutide trials tend to be in the group with the highest baseline cardiovascular and metabolic risk, and many are also taking other supplements. A complete supplement audit matters here.

PCOS

Women with PCOS who are using retatrutide off-label or in trials for metabolic improvement should be aware that insulin resistance itself does not directly raise B6 requirements. Some integrative medicine protocols for PCOS recommend B6 doses in the 50 to 100 mg range for mood and hormone support. These doses are close to or at the UL and should be reviewed with a clinician, especially once retatrutide is added to the regimen.

Pregnancy, Lactation, and Contraception: Non-Negotiable Reading

Retatrutide is not approved for use in pregnancy and must be stopped before trying to conceive.

Here is the detail every woman of reproductive age needs:

Pregnancy

Retatrutide belongs to a class of drugs with animal reproductive toxicity data that raises concern. The FDA label for the approved GLP-1 agonist semaglutide (Ozempic/Wegovy) carries a warning that animal studies showed fetal harm at clinically relevant exposures, and the label recommends discontinuing the drug at least two months before a planned pregnancy. Retatrutide does not yet have an approved label, but based on its shared GLP-1 mechanism and the available preclinical data from Eli Lilly's Phase 2 disclosures, the same precautionary logic applies. Assume retatrutide should be stopped at least two months before attempting conception, and use effective contraception throughout treatment.

Vitamin B6, by contrast, is considered safe in pregnancy at the doses used clinically. The combination of doxylamine 10 mg and pyridoxine 10 mg is FDA-approved for nausea and vomiting of pregnancy, and B6 at doses up to 25 mg/day is routinely used under obstetric guidance. If you become pregnant while taking retatrutide, stop it immediately and contact your clinician and your obstetric provider.

Lactation

No lactation data for retatrutide exists in humans. Given that it is a large peptide molecule, transfer into breast milk is theoretically low, but without safety data, most clinicians will advise against use while breastfeeding. Vitamin B6 does transfer into breast milk, and the RDA for lactating women is 2.0 mg/day; standard dietary intake and prenatal vitamins at that level are safe during breastfeeding.

Contraception requirements

Because retatrutide is an injectable peptide that may affect gastric emptying, there is a theoretical possibility of reducing oral contraceptive absorption. The GLP-1 agonist class guidance from ACOG and clinical pharmacologists suggests that if you rely on oral contraceptives, you should use a barrier method as a backup for the first several weeks after starting any GLP-1-based therapy. A long-acting reversible contraceptive such as an IUD or implant avoids this concern entirely.

Who Is This Combination Right For, and Who Should Reconsider?

Likely fine: standard-dose B6

• Women in reproductive years taking a prenatal or standard multivitamin (B6 content 2 to 25 mg) while on retatrutide trial protocols
• Perimenopausal women on retatrutide for weight and metabolic management who use a multivitamin with standard B6
• Women with PCOS taking low-dose B6 (up to 25 mg) to support mood alongside retatrutide

Discuss with your clinician first: intermediate doses

• Women managing PMS or PMDD with 50 to 100 mg B6 daily; this dose is near or at the UL and may be reducible without losing benefit
• Women on metformin plus retatrutide who already carry some risk of neuropathy (metformin can deplete B12 and, in some individuals, exacerbate peripheral nerve vulnerability)

Reconsider and likely stop high-dose B6

• Women taking 200 mg or more per day of B6 for any reason while on retatrutide; the independent neuropathy risk at these doses is real and documented, and adding a new investigational drug to the picture is not the right time to carry avoidable risk
• Women with pre-existing peripheral neuropathy from diabetes, chemotherapy, or other causes

Monitoring: What to Watch and When to Act

Because retatrutide is investigational and most women taking it are doing so within clinical trials or through off-label compounding channels, active monitoring is more important than with established medications.

Report any of the following to your clinician promptly:

• Numbness, tingling, or burning in the hands, feet, or legs
• New difficulty with balance or coordination
• Unexpected fatigue or muscle weakness

These symptoms could reflect high-dose B6 neuropathy, early diabetic neuropathy, or (rarely) a retatrutide-related adverse effect. Your clinician will want to know which B6 dose you have been taking and for how long.

Checking serum PLP (the active B6 coenzyme) is the most reliable way to assess B6 status. Normal PLP is approximately 30 to 80 nmol/L. Chronic high-dose supplementation can paradoxically saturate and damage peripheral nerves even when serum levels look acceptable, so serum testing alone does not rule out toxicity at very high doses.

Practical Guidance: What to Do If You Are Already Taking Both

If you are already taking vitamin B6 and retatrutide together, here is a clear action list:

1. Check the dose on your B6 label. If it is 25 mg or less, you do not need to change anything based on available evidence.
2. If it is between 25 and 100 mg, schedule a conversation with your prescriber or a registered dietitian to determine whether that dose is clinically necessary for you.
3. If it is above 100 mg, discuss reducing or stopping the high-dose supplement. There is no established therapeutic indication for which B6 above 100 mg/day has been proven definitively superior to lower doses in women.
4. If you experience any new neurological symptoms, stop the high-dose B6 immediately and contact your clinician before your next scheduled appointment.

As WomanRx's reviewing clinician Dr. Maya Okafor, MD, notes: "Most women asking about B6 and retatrutide are taking a prenatal or standard multi, and there is genuinely nothing to worry about at those doses. The women who need to pay attention are the ones buying 250 mg standalone B6 tablets from a supplement store because someone on social media told them it balances hormones. That dose range has real neurotoxicity data behind it, and I would rather we catch that conversation before symptoms start."

Evidence Gaps: What We Do Not Know Yet

Women have been under-represented in metabolic drug trials historically, and retatrutide's Phase 2 data did not report sex-stratified subgroup analyses for supplement use or B6 status in sufficient detail to draw firm conclusions. The SURMOUNT and RETATRUTIDE-2 Phase 3 programs are ongoing, and sex-specific pharmacokinetic data may emerge from those trials. Until then, the following is extrapolated rather than directly studied in women taking retatrutide:

• The magnitude of gastric-emptying-related delay in B6 peak absorption
• Whether the hormonal milieu of perimenopause changes B6 metabolism in the context of GLP-1/GIP/glucagon agonism
• Whether women with PCOS and insulin resistance have meaningfully different B6 kinetics on retatrutide

This honesty matters. Saying "we don't know" is not a reason to avoid the combination at standard doses; it is a reason to avoid high doses where the risk is already documented and the benefit is speculative.